Author: A. Ant, CADC-II, Licensing & Accreditation Expert
California MAT Requirements: More Than Just Methadone Clinics
Most operators think MAT licensing in California means one thing: getting a Narcotic Treatment Program license. That’s half the picture, and the half that’s changed less recently. The other half — a requirement that now applies to nearly every DHCS-licensed or certified SUD program in the state, not just dedicated opioid clinics — is the part we see operators miss.
Narcotic Treatment Programs: the dedicated pathway
If you’re operating a program built specifically around methadone or buprenorphine dispensing, you’re looking at a Narcotic Treatment Program license under Title 9, CCR, Division 4, Chapter 4. This runs through DHCS’s Counselor and Medication Assisted Treatment Section — CMATS, in the acronym-heavy way California does things. The application isn’t a form so much as a protocol document: your program’s operational procedures, organizational structure, and treatment concepts, submitted with a County Alcohol and Drug Program Administrator recommendation attached. Applications without that county recommendation are considered incomplete and get sent back, not held for follow-up. DHCS also expects to see coordination with SAMHSA and DEA registration where applicable, since NTPs sit at the intersection of state licensure and federal opioid treatment program rules.
Mobile Narcotic Treatment Programs are a real, growing category — a vehicle-based extension of a primary NTP’s license, delivering maintenance and withdrawal management services at locations the fixed clinic can’t reach, all still under the parent NTP’s DEA registration and DHCS license.
The part that catches people off guard
Here’s what’s easy to miss: under DHCS’s current guidance (BHIN 23-054), MAT access isn’t limited to programs that hold an NTP license anymore. Any DHCS-licensed or certified SUD program — residential or outpatient, not just narcotic treatment programs — is now expected to offer or facilitate access to FDA-approved medications for substance use disorder. That covers opioid use disorder medications, but it isn’t limited to opioids; it applies to FDA-approved medications for alcohol use disorder too, and to whatever else the FDA approves going forward. A residential program that has never touched methadone can still be out of compliance here if it has no pathway — direct or facilitated through referral — to get a resident access to buprenorphine or naltrexone when clinically indicated.
“Facilitating access” doesn’t mean every facility has to dispense on-site. It means having a real, working relationship with a prescriber or an NTP that can get a patient started without weeks of delay. DHCS’s expectation is that MAT starts as soon as clinically appropriate — particularly when withdrawal symptoms are present — not whenever a referral eventually goes through.
How We Help
We work with California operators on NTP licensure through CMATS, county coordination for the application protocol, and — increasingly — helping non-NTP residential and outpatient programs build a compliant MAT access pathway under BHIN 23-054, since this is one of the more recently enforced pieces of California’s behavioral health regulations. See our California Behavioral Health Licensing page for the broader regulatory picture, or reach out for a free consultation.
This content is provided for general informational purposes only and should not be construed as medical, clinical, legal, financial, tax, accounting, insurance, licensing, accreditation, regulatory, billing, employment, or compliance advice. Requirements change often. Consult qualified professionals or contact Continued Compliance, Inc. for guidance specific to your situation. This article was created by the compliance expert cited above and reviewed by AI. A compliance expert approved and edited it for accuracy before publication.
Leave a Reply